Skip to main content
. 2023 Jan 28;11(2):288. doi: 10.3390/vaccines11020288

Table 6.

Barriers and recommendations.

Barriers Recommendations
General vaccine hesitancy
  • Interventions targeted at barriers of convenience, complacency and confidence [23,44]

  • Behavioural change interventions [107,108]

Lack of perceived trusted information [24,59,70]; concerns over combined vaccines [24,70,81]; concerns over side effects [44,65,82]
  • Annual countrywide measles and MMR awareness programme

  • Web-based decision aid tool providing clear, unbiased and evidence-based information on measles and MMR

  • Official fact-checking for immunisation posts on social media and signposting to valid sources.

Lack of awareness of measles severity and availability of MMR vaccination programme [23,24,59]
  • Annual in-school education campaigns

  • Radio and TV advertisement messages

  • Highlight routine availability of MMR not containing porcine gelatine

Inequalities in service provision [22,65,73,74,75,76,77,103]
  • Annual in-school MMR catch-up and education campaigns

  • Out-of-workday hours vaccination availability

  • Focus on populations most likely not to vaccinate i.e., living in larger households, traveller communities, migrants, looked-after children [23] and children with learning disabilities [65]

  • Foster public health programmes and ethos as in the North East of England [44]

Community-specific needs are not addressed [23,24,71,78]
  • Area-based community and domiciliary immunisation teams

  • Highlight routine availability of MMR not containing porcine gelatine [72]

Inadequate immunisation training [9]
  • Vaccine-specific training for healthcare professionals [51,77]

  • Effective communication and cultural awareness

  • MMR uptake awareness to encourage opportunistic vaccine checks and reduce missed opportunities [24,109]

Lack of advanced information technology for surveillance [13,40]
  • Use novel methods of COVID-19 contact tracing to enhance measles surveillance

Lack of funding [9]
  • Allocated funding for community and domiciliary immunisation teams

  • Use high-visibility campaigns to encourage funding [101]

Vaccine availability and affordability [20,110]
  • This has historically not been an issue in England [111]

  • Novel vaccine delivery innovations including microarray patches, slow-release preparations and enhanced thermostability [112]